Back to Search Start Over

HLA-targeted sequencing reveals the pathogenic role of HLA-B*15:02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature.

Authors :
Liao JM
Zhan Y
Zhang Z
Cui JJ
Yin JY
Source :
Frontiers in pharmacology [Front Pharmacol] 2023 Nov 09; Vol. 14, pp. 1288068. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
Publication Year :
2023

Abstract

Drug-induced liver injury (DILI) is one of the serious adverse drug reactions (ADRs), which belongs to immune-mediated adverse drug reactions (IM-ADRs). As an essential health drug, albendazole has rarely been reported to cause serious liver damage. A young man in his 30 s developed severe jaundice, abnormal transaminases, and poor blood coagulation mechanism after taking albendazole, and eventually developed into severe liver failure. The patient was found heterozygous of HLA-B*15:02 and HLA-B*13:01 through HLA-targeted sequencing, which may have a pathogenic role in the disease. This case report summarizes his presentation, treatment, and prognosis. A useful summary of the diagnosis and associated genetic variant information is provided.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2023 Liao, Zhan, Zhang, Cui and Yin.)

Details

Language :
English
ISSN :
1663-9812
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Report
Accession number :
38027017
Full Text :
https://doi.org/10.3389/fphar.2023.1288068